相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I Study of the Pharmacodynamics and Safety of Sodium Zirconium Cyclosilicate in Healthy Chinese Adults
Tommy Cheung et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2022)
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
Peter Rossing et al.
KIDNEY INTERNATIONAL REPORTS (2022)
The Impact of Hyperkalemia on Mortality and Healthcare Resource Utilization Among Patients With Chronic Kidney Disease: A Matched Cohort Study in China
Jiahui Zhang et al.
FRONTIERS IN PUBLIC HEALTH (2022)
Effects of different potassium-lowering regimens on acute hyperkalemia in hemodialysis patients: a real-world, retrospective study
Lan Yao et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2022)
Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study
Simon D. Roger et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)
Clinical Management of Hyperkalemia
Biff F. Palmer et al.
MAYO CLINIC PROCEEDINGS (2021)
Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE)
W. Frank Peacock et al.
ACADEMIC EMERGENCY MEDICINE (2020)
Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia A 12-Month Phase 3 Study
Bruce S. Spinowitz et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology
Stefano Bianchi et al.
JOURNAL OF NEPHROLOGY (2019)
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia
Steven Fishbane et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE
Simon D. Roger et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
Sheridan M. Hoy
DRUGS (2018)
Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes
Allan J. Collins et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
Achieving the Benefits of a High-Potassium, Paleolithic Diet, Without the Toxicity
Biff F. Palmer et al.
MAYO CLINIC PROCEEDINGS (2016)
A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient
Stephen R. Ash et al.
KIDNEY INTERNATIONAL (2015)
Sodium Zirconium Cyclosilicate in Hyperkalemia
David K. Packham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia The HARMONIZE Randomized Clinical Trial
Mikhail Kosiborod et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Characterization of Structure and Function of ZS-9, α K+ Selective Ion Trap
Fiona Stavros et al.
PLOS ONE (2014)
Prevalence of chronic kidney disease in China: a cross-sectional survey
Luxia Zhang et al.
LANCET (2012)
分享论文
